Azenta sales rise 5% to $622M as impairment drives $158M loss
The Nasdaq-listed life-sciences supplier forecasts revenue of $648M to $660M for fiscal 2027, while flagging corrective quality work in its Automated Stores unit.
Azenta (Nasdaq: AZTA) reported revenue from continuing operations of $622 million for the fiscal year ended 30 September 2026, up 5% on the prior year. Only 2% of that increase was organic. The material available does not explain what accounted for the remaining growth.
The company posted a net loss of $158 million for the year. A $149 million goodwill impairment, an accounting charge that does not involve cash leaving the business, made up more than nine-tenths of that figure. The results were published on 10 November 2026.
For the year ahead, Azenta expects revenue of $648 million to $660 million, roughly 4% to 6% above the fiscal 2026 total. It puts organic growth at 3% to 5% and anticipates its adjusted EBITDA margin widening by about 200 to 250 basis points. The margin level it is starting from is not given in the material on file.
The update also referred to corrective quality work and rework in the Automated Stores business, which makes sample-storage systems. Nothing available indicates how large the problem is, what caused it, when it will be resolved or what it costs, so its effect on earnings cannot be gauged from the information on hand.
Why it matters
- The loss is largely an accounting write-down, so it says little about cash generation; the 2% organic growth figure is the clearer gauge of underlying demand.
- Guidance of 3% to 5% organic growth points to modest rather than rapid expected expansion, with margin improvement doing much of the work on profitability.
- Customers of Azenta's automated sample-storage systems have no operational detail on the quality remediation, so questions about scope and timing would need to go to the company directly.
Company's press release (SEC filing): Azenta, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
